Telomir Pharmaceuticals (NASDAQ: TELO), a clinical-stage biotechnology company developing small-molecule therapeutics targeting epigenetic and metabolic pathways implicated in cancer, announced an approximately $5.6 million private investment in public equity (PIPE) financing through the issuance of 4,843,300 common shares at $1.16 per share, representing a 5% discount to the applicable 10-day volume-weighted average price.
The financing includes an additional $1 million investment from existing significant shareholder John Paul DeJoria and does not include investor warrants, convertible securities or variable-price or reset features. Telomir intends to use the net proceeds primarily to support clinical development of Telomir-Zn, including its Phase 1/2 clinical program in advanced or metastatic triple-negative breast cancer (TNBC), as well as for working capital and general corporate purposes.
The FDA has cleared the company's Investigational New Drug application for Telomir-Zn, enabling it to proceed with its first-in-human Phase 1/2 trial in patients with advanced or metastatic TNBC. This clearance marks a significant milestone for Telomir as it advances its lead program into clinical testing.
For investors, the successful PIPE financing provides Telomir with the necessary capital to fund its clinical development plans without the dilution often associated with warrants or convertible securities. The participation of John Paul DeJoria, an existing significant shareholder, signals continued confidence in the company's direction. The financing structure, with shares priced at a 5% discount to the 10-day VWAP, may be viewed as favorable compared to other financing arrangements that include more complex terms.
The broader biotechnology industry often sees small-cap companies facing challenges in raising capital for clinical trials. Telomir's ability to secure funding at a modest discount and without warrants could indicate investor appetite for its approach to targeting epigenetic and metabolic pathways in cancer. If Telomir-Zn proves successful in clinical trials, it could offer a new therapeutic option for triple-negative breast cancer, a subtype known for its aggressive nature and limited treatment options.
Telomir Pharmaceuticals, Inc. (NASDAQ: TELO) is a clinical-stage biotechnology company developing small-molecule therapeutics targeting epigenetic and metabolic pathways implicated in cancer. The Company's lead program, Telomir-Zn, is designed to modulate intracellular metal homeostasis and epigenetic regulation and has received Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration for a Phase 1/2 clinical trial in patients with advanced or metastatic triple-negative breast cancer.
For more information on Telomir Pharmaceuticals, visit Telomir Pharmaceuticals (NASDAQ: TELO). The latest news and updates relating to TELO are available in the company's newsroom at https://ibn.fm/TELO. To view the full press release, visit https://ibn.fm/0KMpl.
InvestorWire, a specialized communications platform with a focus on advanced wire-grade press release syndication, is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers access to a vast network of wire solutions, including editorial syndication to 5,000+ outlets, enhanced press release enhancement, and social media distribution. For more information, please visit https://www.InvestorWire.com. Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer.
